Capital World Investors Increases Position in Grifols, S.A. (NASDAQ:GRFS)

Capital World Investors raised its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 0.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,134,230 shares of the biotechnology company's stock after purchasing an additional 154,358 shares during the period. Capital World Investors owned 3.07% of Grifols worth $157,239,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in GRFS. GAMMA Investing LLC raised its holdings in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 1,527 shares in the last quarter. HighTower Advisors LLC lifted its position in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 1,546 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Grifols by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 1,657 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Grifols by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock worth $192,000 after buying an additional 2,403 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Grifols during the 4th quarter valued at about $28,000.

Grifols Trading Up 0.4 %

NASDAQ:GRFS traded up $0.03 during midday trading on Friday, hitting $7.21. 1,008,793 shares of the company traded hands, compared to its average volume of 1,207,537. The firm has a market capitalization of $4.96 billion, a P/E ratio of 6.16 and a beta of 0.41. The firm's fifty day moving average is $7.47 and its 200-day moving average is $7.76. Grifols, S.A. has a 12-month low of $5.79 and a 12-month high of $9.96. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley began coverage on Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.